Drug intelligence / Profile preview

LT-102

Development stage: Preclinical
Lead developer: lncTAC Bio
Modality: RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Inhalation, Intranasal, Transdermal

Overview

LT-102 is a preclinical-stage, long non-coding RNA (lncRNA)-based small nucleic acid therapeutic being developed by Chengdu Lingtaike Biotechnology. The drug is designed for the treatment of inflammatory and respiratory conditions, including atopic dermatitis, rhinitis, asthma, and chronic obstructive pulmonary disease (COPD). LT-102 is formulated for delivery via two distinct platforms: a transdermal delivery platform for dermatological indications such as atopic dermatitis, and a respiratory delivery platform for pulmonary and nasal indications like rhinitis, asthma, and COPD.

Targets

AMPAR (AMPA receptor)FOX (FOX (Forkhead box) transcription factors)DLG4 (Disks Large Homolog 4)

Beyond the preview

Go deeper on LT-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LT-102.